|
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Gene expression profiling suggests that Gata2, a hematopoietic transcription factor, is a top upregulated gene in preleukemic Cbfb-MYH11 knockin mice and is expressed in human inv(16) AML.
|
31624376 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM accounts for 1% to 2% of all forms of AML and has been associated with a younger age at diagnosis, a poor response to standard induction chemotherapy, and very poor long-term prognosis.
|
31711889 |
2020 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest that high GATA2 expression is a poor prognostic marker for survival in patients with HR-MDS and LBC-AML treated with azacitidine.
|
31386932 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, GATA2 acts as a critical regulator of normal and leukemic stem cells and mediates transcriptional networks that may be exploited therapeutically to target key facets of LSC behavior in AML.
|
31378673 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Patients with GATA2 mutation have a high risk of developing myelodysplastic syndrome or acute myeloid leukemia.
|
31035956 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Correction: GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy.
|
28350881 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
GATA2 and RUNX1 deficiency is not associated with host susceptibility to DNA damage, and therefore, conventional treatment strategies for MDS and AML can be used.
|
31808891 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
By pooling heterogeneous data from three independent AML cohorts with paired DNA and RNA sequencing (N = 253), we could validate the preferential transcription of GATA2-mutated alleles.
|
31409822 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus, we define novel insights into the oncogenic role of GATA2 in human AML cells and suggest the potential utilization of transient GATA2 therapeutic targeting in AML.
|
31434974 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
GATA-binding protein 2 (GATA2) mutations cause GATA-2 deficiency syndrome involving immunodeficiency, myelodysplastic syndrome, and acute myeloid leukemia.
|
30620726 |
2019 |
|
GATA2 Deficiency
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Germline mutation in GATA2 can lead to GATA2 deficiency characterized by a complex multi-system disorder that can present with many manifestations including variable cytopenias, bone marrow failure, myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), and severe immunodeficiency.
|
30578959 |
2019 |
|
GATA2 Deficiency
|
0.800 |
Biomarker
|
disease |
BEFREE |
Mutational sensitization to stress that instigates hematopoietic failure constitutes a paradigm for GATA-2 deficiency syndrome and other contexts of GATA-2-dependent pathogenesis.
|
30620726 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Genetic predispositions to myeloid malignancies can be classified into three categories: familial cancer syndromes associated with increased risk of various malignancies including myelodysplasia and acute myeloid leukemia such as Li-Fraumeni syndrome and constitutional mismatch repair deficiency (CMMRD); germline mutations conferring a specific increased risk of myelodysplastic syndrome and acute myeloid leukemia such as mutations in ANKRD26, CEBPA, DDX41, ETV6, GATA2, RUNX1, SRP72 genes; and finally primarily pediatric inherited bone marrow failure syndromes such as Fanconi anemia, dyskeratosis congenita, severe congenital neutropenia, Shwachman-Diamond syndrome and Diamond Blackfan anemia.
|
31203998 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Various heteroallelic GATA2 gene mutations are associated with a variety of hematological neoplasms, including myelodysplastic syndromes and leukemias.
|
30710465 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
Biomarker
|
group |
BEFREE |
GATA2 and RUNX1 deficiency is not associated with host susceptibility to DNA damage, and therefore, conventional treatment strategies for MDS and AML can be used.
|
31808891 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
PosttranslationalModification
|
group |
BEFREE |
The methylation profile of the GATA2 promoter region was different between the twins, showing denser promoter methylation in the patient, correlated with MDS.
|
30714451 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
AlteredExpression
|
group |
BEFREE |
Loss and gain of GATA2 expression has been implicated in myelodysplastic syndrome and acute myeloid leukemia (AML) yet the precise biological impact of GATA2 expression on human AML cell fate decisions remains ambiguous.
|
31434974 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
GeneticVariation
|
group |
BEFREE |
A case study is presented of a 33-year-old man with recurrent infections and MDS and his two sons, all of whom were found to have the same GATA2 mutation.
|
31322613 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
GeneticVariation
|
group |
BEFREE |
The GATA2 protein has been shown to be vital for proliferation and maintenance of hematopoietic stem cells; mutations result in variable phenotypes including myelodysplastic syndrome.
|
30933029 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
GeneticVariation
|
group |
BEFREE |
We describe the case of a 17-year-old male presenting with features of nontuberculous mycobacterial infection, pulmonary fibrinoid granulomatous vasculitis, and myelodysplasia in the setting of a pathogenic GATA2 frameshift mutation confirmed by next-generation sequencing.
|
31033783 |
2019 |
|
MYELODYSPLASTIC SYNDROME
|
0.800 |
GeneticVariation
|
group |
BEFREE |
Patients with GATA2 mutation have a high risk of developing myelodysplastic syndrome or acute myeloid leukemia.
|
31035956 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, GATA2 ZF1 mutations are associated with distinct clinico-biological features and predict better prognosis, different from ZF2 mutations, in AML patients.
|
30190467 |
2018 |
|
GATA2 Deficiency
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients.
|
29724903 |
2018 |
|
GATA2 Deficiency
|
0.800 |
Biomarker
|
disease |
BEFREE |
Two previously reported adult GATA2-deficient patients died from severe H1N1 IAV infection; GATA2 deficiency may predispose to life-threatening influenza in adulthood.
|
29882021 |
2018 |
|
GATA2 Deficiency
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics.
|
29077208 |
2018 |